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DNA double-strand breaks (DSBs) occur at
random upon genotoxic stresses and repre-
sent obligatory intermediates during physio-
logical DNA rearrangement events such as
the V(D)J recombination in the immune sys-
tem. DSBs, which are among the most toxic
DNA lesions, are preferentially repaired by
thenonhomologousend-joining (NHEJ)path-
way in higher eukaryotes. Failure to properly
repair DSBs results in genetic instability,
developmental delay, and various forms of
immunodeficiency. Here we describe five pa-
tients with growth retardation, microcephaly,
and immunodeficiency characterized by
a profound T+B lymphocytopenia. An in-
creased cellular sensitivity to ionizing radia-
tion, a defective V(D)J recombination, and
an impaired DNA-end ligation process both
in vivo and in vitro are indicative of a general
DNA repair defect in these patients. All five
patients carry mutations in the Cernunnos
gene, which was identified through cDNA
functional complementation cloning. Cer-
nunnos/XLF represents a novel DNA repair
factor essential for the NHEJ pathway.
INTRODUCTION
DNA double-strand breaks (DSBs) are among the most toxic
DNA lesions caused by cell-intrinsic sources such as replica-
tion errors or other DNA-damaging agents naturally presentin cells, including reactive oxygen species. DSBs can also re-
sult from exposure to a variety of extrinsic factors, including
ionizing radiation (IR). Lastly, DSBs represent obligatory inter-
mediates of physiological DNA rearrangement processes
taking place during the development and maturation of the
adaptive immune system (V[D]J recombination and immuno-
globulin [Ig] heavy chain class switch recombination [CSR])
(Sancar et al., 2004). The V(D)J recombination is a somatic
DNA rearrangement of Variable, Diversity, and Joining gene
segments encoding the T and B cell antigen receptor loci.
The lymphoid-specific recombination activating gene (RAG)
1 and 2 encoded endonuclease initiates the reaction by intro-
ducing a DSB at recombination-specific sequences (RSS)
that flank all V, D, and J gene units (Bassing et al., 2002).
The efficient repair of DNA DSBs introduced during these re-
actions is required to maintain genome integrity, thus pre-
venting the development of cancer and other ‘‘DNA instabil-
ity’’ disorders. DSBs are primarily repaired by the accurate
homologous recombination (HR) in yeast and by the error-
prone nonhomologous end-joining (NHEJ) pathway in higher
eukaryotes (Sancar et al., 2004). To date, six mammalian fac-
tors have been identified as constituting the core NHEJ appa-
ratus involved in V(D)J recombination. The Ku70/Ku80 heter-
odimer binds to DNA ends, present at RAG1/2-generated
DSBs, and recruits the ATM-related kinase DNA-PKcs (Got-
tlieb and Jackson, 1993; Dynan and Yoo, 1998). DNA-PKcs
then phosphorylates and activates the Artemis endonucle-
ase, the enzyme required to resolve DNA hairpin structures
created upon RAG1/2-specific DNA cleavage (Ma et al.,
2002). The XRCC4/DNA-LigaseIV (Lig4) complex is respon-
sible for the final ligation step (Grawunder et al., 1997).
The fundamental role of NHEJ factors in the immune system
has been recognized through genetic deletion in mice and
studies of specific human conditions (de Villartay et al., 2003).
In all animal models, NHEJ defects result in the arrest of B
and T lymphocyte maturation, accompanied by an embryonic
lethality in the case of XRCC4 and Lig4 deficiencies (Dudley
et al., 2005; Revy et al., 2005). In humans, null mutations inCell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc. 287
Table 1. Clinical Features of Patients
Patients Origin Consanguinity Microcephaly
Growth
Retardation
Associated
Clinical
Features Infections Autoimmunity Outcome
P1 French no yes yes chromosomal
alterations,
urogenital
and bone
malformations
bacterial
and
oppor-
tunistic
autoimmune
anemia and
thrombo-
cytopenia
died at
18 years:
septic
shock
P2 Turkish +, 1st degree yes yes no bacterial
and
oppor-
tunistic
no died at
4 years:
septic
shock
P3* Turkish +, 1st degree yes yes birdlike face,
bone malfor-
mation
bacterial
and
oppor-
tunistic
autoimmune
anemia and
thrombo-
cytopenia
alive:
14 years
old
P4* Turkish +, 1st degree yes yes birdlike face bacterial
and
oppor-
tunistic
no alive:
3 years
old
P5 Italian +, 3rd degree yes yes birdlike face,
chromosomal
alterations,
bone marrow
aplasia
recurrent
respira-
tory tract
infections
no alive:
9 years
old
* P3 and P4 are siblings.Artemis result in RS-SCID, characterized by a complete ab-
sence of peripheral T and B lymphocytes and an increased
cellular sensitivity to IR (Moshous et al., 2001). Variable immu-
nodeficiency, developmental delay, chromosome alterations,
and microcephaly have also been attributed to hypomorphic
mutations in the Lig4 gene in humans (O’Driscoll et al., 2001;
Buck et al., 2006). Finally, a radiosensitive SCID condition
(patient 2BN) without mutation in any of the known NHEJ
factors was identified, supporting the existence of additional
uncharacterized DNA repair factors (Dai et al., 2003).
With the aim of identifying new factors involved in general
DNA repair, we undertook a systematic survey of human con-
ditions characterized by developmental anomalies, such as
microcephaly, associated with various degrees of immune
deficiency and/or the onset of lymphopoietic malignancy. In
this article, we describe a new syndrome of human combined
immunodeficiency (CID) associated with microcephaly and
increased cellular sensitivity to IR. This condition is caused
by a general DNA repair defect owing to mutations in a novel
NHEJ factor encoding gene, Cernunnos.
RESULTS
A New Syndrome Associated with T and B Cell
Combined Immunodeficiency, Growth Retardation,
and Microcephaly
The main clinical features characterizing the patients in-
cluded in this study were growth retardation, microcephaly,288 Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc.and immunodeficiency (for detailed case reports, see Exper-
imental Procedures and Tables 1 and 2). Severe growth retar-
dation and dystrophy were observed in four of the five pa-
tients, and microcephaly was present in all five patients at
birth. Dysmorphic features and various malformations were
observed in four of the patients (Table 1). Recurrent infections
of bacterial, viral, and/or parasitic origin occurred in all pa-
tients and were lethal in two. Laboratory analysis indicated
a mild to severe B (CD19+) and T (CD3+) lymphocytopenia
in all patients, whereas the NK cell subset was not affected
(Table 2). Circulating B cell counts declined with age from
close to normal values to undetectable levels, and most pa-
tients displayed hypogammaglobulinemia affecting IgG and
IgA, accompanied by fluctuating levels of IgM (Table 2). The
T lymphocyte subsets were composed only of memory T
cells (CD45RO positive) with impaired functions determined
by low in vitro PHA mitogen-induced T cell proliferation.
In association with microcephaly, the absence of circulat-
ing naı¨ve T cells and the progressive disappearance of B
cells were indicative of a molecular defect affecting the mat-
uration of the immune system as observed in Lig4 deficient
or Nijmegen breakage syndrome (NBS) patients.
Increased Radiosensitivity of Patients’ Fibroblasts
Lig4 and NBS conditions are two DNA repair deficiencies
characterized by an increased cellular sensitivity to IR (Varon
et al., 1998; O’Driscoll et al., 2001; Buck et al., 2006). Pri-
mary skin fibroblasts from four of the tested patients (P1-
P4) exhibited an increased sensitivity to g ray exposure as
Table 2. Immunological Characteristics of Patients
Patients P1 P2 P3 P4 P5
Age at diagnosis
(years)
14 2 13 2 7
Lymphocyte
countsa
750 (1400–3300) 1220 (2300–5400) 1610 (1400–3300) 2570 (2300–5400) 1101 (1900–3700)
T lymphocytesa 630 (1000–2200) 730 (1400–3700) 870 (1000–2200) 591 (1400–3700) 693 (1200–2600)
T CD4+a 428 (530–1300) 150 (650–1500) 490 (530–1300) 334 (650–1500) 319 (530–1300)
CD45RO/T
CD4 (%)
99 (18–38) 98 (9–26) 87 (18–38) 98 (9–26) 99 (13–30)
T CD8+a 248 (330–920) 559 (370–1100) 370 (330–920) 77 (370–1100) 330 (330–920)
CD45RO/T
CD8 (%)
92 (4–23) 54 (4–16) 65 (4–23) n.i. 83 (4–21)
B lymphocytesa 0 (110–570) 75 (390–1400) 0 (110–570) 154 (390–1400) 44 (110–570)
NK cellsa n.d. 281 (92–918) 402 (42–726) 1336 (92–918) 195 (76–629)
T cell proliferation
PHAb
30 (>40) 5.8 (>40) 119 (>40) 84 (>40) 16 (>40)
Ig values before
substitution
IgGc 2.4 (6.4–14.2) <0.33 (5.2–10.8) <0.5 (2.8–6.8)* 2.37 (maternal;
2.7–5.3)**
0.6 (5.7–13.2)
IgAc <0.06 (0.52–2.2) <0.06 (0.36–1.65) <0.5 (0.1–0.58)* <0.05 (0.02–0.22)** 0.06 (0.65–2.4)
IgMc 6.8 (0.4–1.8) 1.39 (0.72–1.60) 0.15 (0.4–0.84)* 0.27 (0.36–0.56)** 1.05 (0.6–1.75)
n.d.: not done.
n.i.: not interpretable.
Age-matched control values are from Shearer et al. (Shearer et al., 2003) and are shown in italics in parentheses. Tested at *5 or
**3 months of age.
a in counts/ml; presence of maternal T cells was excluded by HLA typing of sorted T cells.
b Phytohemagglutinin (PHA)-induced proliferations are expressed as counts per minute  103.
c in mg/ml.compared to control cells in a clonogenic assay (Figure 1A).
Although the level of IR sensitivity was variable among the
patients, it was equivalent or sometimes more pronounced
than what was observed in other radiosensitive conditions,
such as Ataxia telangiectasia (A-T), NBS, Lig4, or Artemis
deficiencies (Figure 1A and data not shown).
IR-Induced Foci Formation Is Normal
in Patients’ Fibroblasts
The phosphorylation of the histone variant H2AX (then called
gH2AX) occurs rapidly in response to a DNA-DSB (Rogakou
et al., 1998) and is essential to keeping DNA ends in close
proximity and to stabilizing the association of DNA-repair
factors such as the MRE11-RAD50-NBS1 (MRN) complex
and 53BP1 at the site of the damage (Bassing and Alt,
2004), forming ionizing radiation-induced foci (IRIF). gH2AX,
MRE11, 53BP1, and RAD51 IRIFs were equally well formed
in P1-P4 and control fibroblasts 2 hr after 10 Gy irradiation
(Figures 1B and S1 and data not shown). This result sug-
gests that the increased sensitivity to IR does not result
from a defect in the initial DNA damage sensing. In contrastto normal control cells, gH2AX signal persisted in patients’
cells 24 hr following DSB induction, as observed by both mi-
croscopy and fluorocytometry, signifying a major DNA repair
defect in these cells (Figure 1B and data not shown).
Normal Cell-Cycle Checkpoints in Patients’
Fibroblasts Following IR
IR induce cell-cycle checkpoints, which can be analyzed at
three critical steps: the inhibition of entry into the S phase
(G1/S checkpoint), the S phase progression, and the inhibi-
tion of entry into mitosis (G2/M checkpoint). The G1/S
checkpoint following a 5 Gy IR was comparable in all pa-
tients’ and controls’ fibroblasts with a 75% mean inhibition
of S phase entry (Figures 1C and 1D). This contrasted with
the defect of this checkpoint in fibroblasts from A-T or
NBS patients (Figures 1C and 1D). The S phase progression,
analyzed through radioresistant DNA synthesis (RDS) assay,
was also similarly inhibited in patients’ and controls’ fibro-
blasts following IR (Figure S2). Lastly, we examined the IR-
induced G2/M checkpoint by analyzing the phosphorylation
of the Histone 3 (H3) (Figure 1E). H3 phosphorylation (P-H3)Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc. 289
Figure 1. Cellular Response to DNA Damage
(A) Survival of primary fibroblasts after IR (up to 3 Gy). Results are expressed as the fraction of colony-forming cells in relation to unirradiated cells. Each point
represents the mean value and standard deviation of three separate determinations. Control radiosensitive fibroblasts were from Lig4 (L4), A-T, and NBS
patients.
(B) Left panel: Primary fibroblasts from the control and P1 were seeded onto glass slides and either left untreated or else irradiated with 10 Gy and fixed 2 or
24 hr postirradiation before staining with anti-gH2AX. Nuclei were stained with DAPI. Right panel: gH2AX detection by fluorocytometry was performed in
untreated fibroblasts (black curve) and 30 min (red curve) or 24 hr (green curve) post-DSB induction. Persistence of gH2AX signal at 24 hr posttreatment in
patients’ cells in both experiments is indicative of a general DNA-repair defect.290 Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc.
correlates with chromosome condensation occurring imme-
diately before mitosis (Wei et al., 1999). The 80% decrease
in P-H3-positive cells in patients’ and controls’ fibroblasts
following a 5 Gy IR (Figures 1E and 1F) indicated a normal
G2/M checkpoint and contrasted with the impaired G2/M
checkpoint in A-T cells. Altogether, these results demon-
strated that the IR-induced biochemical events leading to
the various cell-cycle checkpoints were not altered in this
group of patients.
These observations suggested that these patients, al-
though presenting clinical manifestations similar to those
seen in A-T or NBS conditions, clearly differ from these two
settings. In addition, the normal DNA-damage sensing, IRIF
detection, and IR-induced cell-cycle control indicate that
the increased cellular radiosensitivity and gH2AX persistence
result from an intrinsic defect in DNA repair.
Defect in the NHEJ Process
In Vivo DNA-Ligation Assay
To analyze the ability of patients’ cells to join double-
stranded DNA ends by the NHEJ pathway, fibroblasts
were transfected with restriction-enzyme-digested, linear-
ized plasmids containing either blunt-blunt or incompatible
30-30 overhang ends. Recircularized plasmids were recov-
ered 48 hr after transfection, and their junctions were ana-
lyzed by DNA sequencing. The junctions in plasmids recov-
ered from two of the control cell lines (C-1 and C-2) were
relatively accurate (71% to 95%), independently of the nature
of the DNA-ends (Figures 2A, 2B, and 2C). In striking con-
trast, in plasmids recovered from the three of the tested pa-
tients’ cell lines (P1, P2, and P5), the junctions were rarely ac-
curate (0% to 16%), irrespective of the nature of the DNA
ends (Figures 2A, 2B, and 2C). These junctions involved var-
ious degrees of nucleotide deletion. The mean number of nu-
cleotide loss in inaccurate junctions was significantly higher
(p < 0.001) in plasmids recovered from patients’ cells than
in those recovered from controls (Figure 2D).
V(D)J Recombination
Because of its critical dependency on a functional NHEJ ma-
chinery, we next analyzed V(D)J recombination in patients
fibroblasts upon transfection of the pRecCS extrachromo-
somal V(D)J recombination substrate and the human
full-length lymphoid-specific RAG1- and RAG2-expressing
constructs (Nicolas et al., 1998). Coding and signal-join for-
mation, identified by specific PCR amplification of recovered
rearranged pRecCS plasmids, was similar or reduced in pa-
tients’ fibroblasts as compared to control (Figure 3A). Re-
duced V(D)J recombination activity was further documentedin P1 and P2 using an in-chromosome V(D)J assay (Fig-
ure S4). Sequence analysis of recovered, rearranged sub-
strates revealed a slight increase in nucleotide loss in coding
joins (Figure S3A) compare to controls but not the major al-
terations typically observed in other NHEJ deficiency situa-
tions (Bogue et al., 1997; Rooney et al., 2002; Rooney
et al., 2003). In particular, these junctions were not charac-
terized by extensive nucleotide loss or long P nucleotides.
In contrast, the fidelity of signal joins was severely impaired
in patients’ cells. This was first demonstrated by the resis-
tance to ApalI digestion, a restriction-enzyme site created
by the perfect fusion of RSS in normal signal joins (Figure 3B).
Sequence analysis revealed that 45% of signal joins were im-
precise, with nucleotide loss ranging from 6 to 17 bp (Fig-
ure S3B). Several sequences suggested the possible usage
of microhomology during joining. These V(D)J recombination
anomalies are a characteristic feature previously recognized
in NHEJ-deficient fibroblasts from Lig4 patients (Badie et al.,
1997; Riballo et al., 2001; Buck et al., 2006) and in 2BN cells
(Dai et al., 2003).
The V(D)J deficiency in these patients is less severe than in
Artemis-deficient RS-SCIDs and probably accounts for the
presence of low counts of B and T cells in these patients.
In Vitro NHEJ Assay
Lastly, we analyzed the in vitro end-joining of linearized plas-
mid DNA by using cell-free extracts (Baumann and West,
1998; Diggle et al., 2003). This DNA-end ligation assay,
which results in the formation of DNA concatemers when us-
ing control extracts (Figure 3C, lane C), requires a functional
NHEJ apparatus, as demonstrated by the absence of DNA
oligomers when using extract from a Lig4 deficient patient
(L4). Defective DNA multimerization when using extracts
from P1-P5 (Figure 3C) strongly argued for a NHEJ defect
in these patients. Importantly, the patients’ extracts cross-
complemented the L4 extract in this assay (Figure 3D),
thus eliminating a DNA Lig4 deficiency in P1-P5. Finally,
pair-wise mixing of P1-P5 extracts failed to complement
the absence of DNA end-joining (Figure 4E), suggesting
that the molecular defect may be identical in the five patients.
In conclusion, these data indicated that the five patients
present with an identical general DNA-repair defect affecting
the NHEJ machinery. This molecular defect translates into
an increased cellular sensitivity to DNA-damaging agents
in vitro and subsequently into a major failure in the develop-
ment of both B and T lymphocytes in vivo, thus resulting in
a combined immunodeficiency. Although these features
are known to be shared by Lig4-deficient patients, a Lig4
gene defect was excluded in all five of our patients.(C) BrdU incorporation in proliferating cells and DNA content were analyzed either in untreated or in 5 Gy irradiated cells from a control, an A-T patient, and
P1 as a means of analyzing the G1/S cell-cycle checkpoint. While A-T cells did not arrest cycling following IR, P1 cells did.
(D) The fraction of cells in early S phase was determined by FACS analysis with and without 5 Gy IR, as in (C), and was used to calculate the inhibition of S
phase entry. A-T and NBS cells were defective in G1/S checkpoints, whereas P1-P5 cells behaved like normal controls.
(E) The phosphorylation of histone H3 and DNA content of either untreated or of 5 Gy-irradiated P1 cells were analyzed by FACS. While A-T cells retained
phospho-H3-positive cells following IR, indicating their impaired G2/M checkpoint, P1 cells did not.
(F) The fraction of phospho-H3 positive cells in IR and untreated cells was used to calculate the % inhibition of entry into mitosis in A-T and control cells as
well as into cells from P1, P2, and P5. While A-T cells demonstrate a defect in the G2/M checkpoint following IR, patients’ cells behaved like normal controls.Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc. 291
Figure 2. DNA-End Ligation of Linearized Plasmids Is Defective in Patients’ Fibroblasts
(A) DNA sequence of junctions was obtained after ligation of blunt-blunt linearized plasmids in fibroblasts from two controls (C-1 and C-2) and patients P1,
P2, and P5. The occurrence of a given sequence is indicated on the right.
(B) DNA sequence of junctions was obtained after ligation of 30-30 linearized plasmid in fibroblasts from two controls (C-1 and C-2) and patients P1 and P2.
The occurrence of a particular sequence is indicated on the right.
(C) Percentages (mean values and standard deviations) of accurate junctions in clones from each set of experiments depicted in (A) and (B). Accurate junc-
tions are defined as the sequences preponderantly shared by the two controls.
(D) Chart representing the mean nucleotide loss in inaccurate junctions observed under the two experimental conditions.Cloning of Cernunnos cDNA
Genetic analysis using highly polymorphic microsatellite
markers allowed us to formally exclude a role for the six
known NHEJ factor-encoding genes Ku70, Ku80, DNA-
PKcs, Lig4, XRCC4, and Artemis in the four patients (P2-
P5) who were born to three consanguineous families since
transmission of the disease was independent from the seg-
regation of markers flanking the above-mentioned genes
(not shown). We designed a functional complementation292 Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc.cloning strategy based on the rescue of the increased cel-
lular sensitivity to DNA-damaging agents to identify the de-
fective gene. A human thymic cDNA library was introduced
into P2 fibroblasts by means of retroviral transduction. Eight
separate pools of transduced cells were then treated nine
times with the radiomimetic drug bleomycin (0.5 mg/ml)
over a period of 88 days. Transduced cDNAs were recov-
ered by PCR amplification of genomic DNA with vector-spe-
cific flanking primers. This resulted in discrete bands (from 1
Figure 3. V(D)J Recombination in Fibroblasts and In Vitro NHEJ Are Defective in Patients
(A) SV40-transformed fibroblasts were transfected with RAG1- and RAG2-expressing vectors and the pRecCS extrachromosomal V(D)J recombination
substrate. The substrate was recovered 48–72 hr posttransfection, and the formation of signal and coding joins were analyzed by PCR.
(B) The signal-join fidelity was analyzed by ApalI digestion of the PCR products. Signal joins detected in P1 and P3 were imprecise.
(C) Protein extracts from control (C), a Lig4 patient (L4), and P1-P5 cells were incubated with a linearized plasmid. The reaction products were run on aga-
rose gel and stained with SYBR-Green. Multimerized DNA molecules (2 and 3) were formed with control but not with P1-P5 extracts.
(D) While mixing protein extracts from Lig4 (L4) together with P1-P5 cells eliminated the NHEJ defect, using either one independently resulted in the emer-
gence of the defect, indicating that P1-P5 defect is not Lig4.
(E) Pair-wisemixingofP1-P5cellular extracts failed tocomplement the patient’sNHEJ defect, suggesting thatP1-P5belong to thesamecomplementationgroup.to 6) in all eight pools of transduced cells (data not shown),
which suggested a specific outgrowth of cells that had re-
ceived a cDNA complementing their endogenous gene de-
fect. DNA sequencing identified an identical cDNA present
in the PCR products from seven of the pools.
This cDNA (EMBL:AJ972687) covers 2063 nucleotides
and encodes a hypothetical protein of 299 amino acids
(aa), which we named Cernunnos (Figure 4A). The Cernun-
nos gene (GeneID: 79840), located on human chromosome
2q35, is composed of eight exons with sizes ranging from 59
bp to 1130 bp (Figure 4B). The Cernunnos gene has never
been described previously (except for the in silico-derived
hypothetical protein FLJ12610), and database searching
did not disclose any obvious homology with other known
proteins or functional domains. cDNA cloning of the murine
Cernunnos counterpart revealed a 74% protein identity
over the whole sequence, suggesting a high degree of con-
servation among higher eukaryotes (not shown). RT-PCR
analysis of a panel of 15 cDNAs representing a wide range
of human tissues demonstrated that Cernunnos is ubiqui-
tously expressed (Figure 4C). Finally, immunofluorescence
analysis of ectopically expressed, V5 epitope-tagged Cer-
nunnos in fibroblasts revealed a predominant nuclear locali-zation (Figure 4D). These last two findings are compatible
with Cernunnos being a general DNA repair factor.
Cernunnos Mutations
Mutations affecting the Cernunnos encoding gene were
identified in all five patients (Figure 4B). P1 carries two mis-
sense heterozygous mutations, C259G (cDNA) in exon 2
and T457C in exon 3, leading to R57G and C123R aa sub-
stitutions respectively. P2 displays a homozygous C622T
nonsense mutation in exon 5, changing an arginine codon
at position 178 to a stop codon (R178X), thus resulting in
a putative protein lacking about one-third of the C terminus
region. P3 and P4 carry a homozygous deletion of G267,
the last nucleotide of exon 2, as well as a homozygous A
to T change three nucleotides downstream in intron 2 (Fig-
ure 4B). These two associated mutations result in a mixed
RNA population. Normally spliced RNAs carry the G267 de-
letion, resulting in a frameshift at K69 followed by a premature
stop codon, while numerous aberrant splicing events lead to
severely truncated putative proteins. Of note, one of these
mutated forms may retain some activity as it presents an in-
ternal in-frame deletion covering A25-R57 (data not shown).
Lastly, P5 carries a homozygous C259G substitution in exonCell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc. 293
294 Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc.
2, resulting in R57G aa modification. We confirmed the auto-
somal recessive inheritance of the identified mutations by
sequencing parents’ DNA in all cases (data not shown).
Complementation of the NHEJ Defect
by wt Cernunnos
We next evaluated the complementation of the NHEJ defect
by ectopic expression of wt Cernunnos. Primary fibroblasts
from P1, P2, and P3 were transduced with a bicistronic
Cernunnos-ires-GFP retrovirus, resulting in 86%, 75%, and
80% GFP-positive cells respectively. The survival curves of
these transduced cells after ionizing radiation (0, 1, and 3
Gy) indicated a return to an overall normal radiosensitivity
as compared to control cells (Figure 5A). Likewise, the
V(D)J recombination was fully restored upon transfection of
wt Cernunnos, as demonstrated by the complete ApalI di-
gestion of PCR-amplified signal joins (Figure 5B) and in-
chromosome V(D)J assay (Figure S4). Lastly, cell-free ex-
tracts from Cernunnos-transfected fibroblasts were able to
oligomerize linear DNA molecules in the in vitro NHEJ assay
(Figure 5C). Taken together, these results confirm that the
identified Cernunnos mutations are responsible for the de-
fective DNA repair in this series of patients.
DISCUSSION
T and B Cell Combined Immunodeficiency,
Microcephaly, and Growth Retardation
Caused by Cernunnos Mutations
We herein describe a T and B cell combined immunodefi-
ciency characterized by a progressive lymphocytopenia as-
sociated with developmental defects including microcephaly
as well as growth retardation and an increased cellular sen-
sitivity to IR. This new rare human autosomal recessive pri-
mary immunodeficiency is caused by deleterious mutations
in a novel general DNA repair factor we have named Cernun-
nos. The independent identification of the same factor,
named XLF, is reported by Ahnesorg et al. in another article
in this issue ofCell (Ahnesorg et al., 2006). Strikingly, the clin-
ical phenotype of Cernunnos-deficient patients shares sev-
eral characteristics with Nijmegen breakage syndrome and
Lig4 deficiency. However, Cernunnos deficiency does not
lead to impaired cell-cycle checkpoints, as observed in NBS
condition, but leads rather to an NHEJ defect as observed in
Lig4 deficiency as well as in the 2BN patient (Carney et al.,
1998; Matsuura et al., 1998; Varon et al., 1998; Dai et al.,
2003; Buck et al., 2006).
DSB are introduced in DNA during the V(D)J recombination
process. A complete failure to resolve these breaks leads to
an arrest in B and T cell development, as observed in Arte-
mis-deficient RS-SCID condition and in the respective animalmodels (Revy et al., 2005). A residual DNA end-joining activ-
ity, as observed in the case of hypomorphic Lig4 and Artemis
mutations, allows for limited development of B and T cells
(Moshous et al., 2003; Smith et al., 2003). The partially com-
promised (around 10% of normal value as shown in Figure
S4C) V(D)J recombination identified in Cernunnos-deficient
fibroblasts is comparable to that of hypomorphic Lig4-defi-
cient cells and may account for the severe T and B cell lym-
phopenia observed in Cernunnos deficiency. The low counts
of circulating T and B cells may in fact reflect a residual Cer-
nunnos activity caused by hypomorphic mutations. The na-
ture of the different mutations identified in the patients is com-
patible with expression of a Cernunnos protein, albeit
truncated in some cases (P2-P4). In Cernunnos patients,
the presence of memory-only T cells in combination with
the progressive loss of B lymphocytes suggest that while
a wave of lymphocyte production did occur at some point,
the sustained renewal of the immune system is profoundly
impaired in these patients. These observations, taken to-
gether with our observation of the occurrence of bone mar-
row aplasia in P5, suggest that the Cernunnos defect may
be associated with a compromised haemo-/lymphopoiesis.
T cell lymphopenia appears relatively milder as compared
to B cell, at least in the eldest patients. Expansion of long-
lived memory T cells as observed in other combined T+B im-
munodeficiencies caused by other hypomorphic gene muta-
tions (DiSanto et al., 1994; Moshous et al., 2003; De Villartay
et al., 2005) can account for this observation.
Although patients displayed a hypogamaglobulinemia, the
levels of serum IgM (Table 1) were occasionally as high as
observed in classical CSR-deficient hyper-IgM syndromes
(Durandy et al., 2005). This suggests a possible role for Cer-
nunnos in CSR. Autoimmunity is another consequence of
the immunodeficiency caused by Cernunnos deficiency, as
also observed in other combined T+B cell immunodefi-
ciencies caused by hypomorphic mutation of RAG1 (De Vil-
lartay et al., 2005). It may result from a skewed T cell reper-
toire subsequent to partially defective T+B development or
to defective peripheral control of response to self antigens.
Beside the patent immunological consequences of Cer-
nunnos deficiency, developmental defects, notably micro-
cephaly, are also present. This is reminiscent of the micro-
cephaly that has been noted in some Lig4-deficient
patients (Riballo et al., 1999; O’Driscoll et al., 2001; Buck
et al., 2006), as well as of the embryonic lethality of Lig4
(and XRCC4) KO mice due to massive apoptosis of postmi-
totic neurons (Barnes et al., 1998; Frank et al., 1998; Gao
et al., 1998). This suggests that Cernunnos plays a role in
the development of the central nervous system. Indeed, pro-
ficient DNA-damage responses, including NHEJ and HR,
have been shown to be essential during the developmentFigure 4. Cernunnos: cDNA Sequence, Genomic Organization, Patients’ Mutations, cDNA Expression, and Subcellular Localiza-
tion
(A) Cernunnos cDNA sequence and protein (1-letter code).
(B) Cernunnos gene organization with the mutations identified in patients. Gray regions represent the coding sequence.
(C) RT-PCR analysis using a panel of cDNA from 15 different human tissues. G3PDH-specific primers were used as control.
(D) Nuclear localization of transfected V5-epitope-tagged Cernunnos in fibroblasts determined by immunofluorescence.Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc. 295
Figure 5. Complementation of the DNA-Repair Defect by wt Cernunnos
(A) Primary fibroblasts from P1 (squares), P2 (circles), and P3 (triangles) were transduced with Cernunnos-iresGFP retrovirus and exposed to ionizing ra-
diation (solid lines), and their survival compared to untransduced cells (dash lines) and normal control cells (gray envelope).
(B) V(D)J recombination coding join-formation and signal join-fidelity (complete ApalI digestion) were restored by wt Cernunnos in P1-P5 fibroblasts.
(C) Wt Cernunnos complemented the in vitro NHEJ defect in cellular extracts from transfected P1-P5 cells.of the brain (Abner and McKinnon, 2004). Whether Cernun-
nos, comparably to Lig4/XRCC4, is an essential factor for vi-
ability is currently unknown. The development of a Cer-
nunnos KO mouse is likely to assist in clarifying this issue.
NHEJ factors are considered genomic caretakers since
they guarantee genomic integrity through the proper repair
of DNA lesions (Ferguson and Alt, 2001; Dudley et al.,
2005; Revy et al., 2005). Indeed, analysis of several animal
models has indicated that NHEJ deficiency may result in
chromosomal aberrations such as translocations or telo-
meric fusions, the consequence of which is a high propensity
to develop cancer. In the immune system, the introduction of
an NHEJ defect into a P53 mutated background invariably
leads to the development of pro-B cell lymphomas in mice
(Ferguson and Alt, 2001). Likewise, hypomorphic mutations
in Lig4 and Artemis in humans have been found to be asso-
ciated with the onset of lymphopoietic malignancies (Riballo
et al., 1999; Moshous et al., 2003). The question of the ge-
nomic caretaker status of Cernunnos is of importance be-
cause it may turn out that Cernunnos deficiencies are linked
to a higher risk of developing cancer. The implication of Cer-
nunnos in NHEJ in combination with the fact that two Cer-
nunnos deficient patients (P1 and P5) exhibited several chro-
mosome alterations support this assumption. The analysis of
Cernunnos KO mice will help to clarify this important issue.
What Is the Role for Cernunnos in NHEJ?
The in vitro NHEJ assay clearly identified Cernunnos as a key
constituent of the DNA end-joining reaction. The remarkable
parallel in the clinical/biological presentations of Cernunnos
with Lig4 deficiencies strongly suggests that Cernunnos
could be a third partner in the XRCC4/Lig4 complex. Indeed,296 Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc.the accompanying article from Stephen Jackson’s labora-
tory reports on the identification of the same factor (named
XLF) through two-hybrid screen using XRCC4. Moreover,
the interaction of Cernunnos/XLF with the XRCC4:DNA-Li-
gaseIV complex in vivo was further documented through
coimmunoprecipitation experiments (Ahnesorg et al., 2006
and unpublished data). Several biochemical and genetic
studies in yeast and mammals have previously identified
XRCC4 and/or Lig4 interacting factors. Among those,
Nej1/Lif2p has been described only in S. cerevisae (Frank-
Vaillant and Marcand, 2001; Kegel et al., 2001; Ooi et al.,
2001; Valencia et al., 2001). Nej1 interacts with the yeast
XRCC4 homolog (Lif1) and is critically required for NHEJ.
Moreover, Nej1 is specifically repressed during mating
type-switching in yeast, a DNA recombination process that
relies exclusively on homologous recombination. No homo-
logs for Nej1 have yet been identified in higher eukaryotes.
Further studies are now required to determine whether or
not Cernunnos represents a functional, although highly di-
vergent, homolog of Nej1 in mammals.
EXPERIMENTAL PROCEDURES
Patients
The patients’ clinical phenotypes are shown in Table 1.
Five patients from four families (including three consanguineous fami-
lies) were included. P3 and P4 were siblings. Family history revealed
that three older sisters of P2 died from severe infections during their first
year of life. All patients presented with growth retardation (-3SD), already
existent at birth in two of them, or during the first year of life in the other
three. Microcephaly (-3SD) at birth was a constant feature in all patients.
Facial dysmorphia was mild in P1 but was more prominent in P3-P4 and
P5, who presented with a birdlike face. Bone malformations were present
in P1 (i.e., low implantation of the thumb) and in P3-P4 (i.e., hypoplasia of
the middle phalanx of the fifth finger). Malformations of the kidney (i.e.,
nephroptosis) and of the genital organs were also present in P1. Mental
retardation was evident only in P1. P5 suffered from bone-marrow apla-
sia, which was first diagnosed at the age of one year. Chromosomal anal-
yses revealed a normal 46XY karyotype but several spontaneous, nonre-
current, chromosomal translocations in patients P1 and P5 lymphocytes.
All patients experienced severe infections; P1 developed recurrent
bacterial infections of the respiratory tract beginning at the age of three
years and invasive warts and a life-threatening cholangitis which had
been diagnosed at eight years of age. P2 suffered from recurrent bacterial
infections of the respiratory and digestive tracts from the first months of life
onward. P3 presented with a Pneumocystis carinii pneumonia, chronic
Giardia lamblia enteritis, and Salmonella and Campylobacter enteritis as
well as molluscum contagiosum and warts from three years of age on-
ward. His sister, P4, had neonatal pneumonia and suffered from mild re-
current infections of the upper respiratory tract. P5 developed bacterial in-
fections of the respiratory tract from the first year of life onward. Two
patients (P1 and P3) also developed autoimmune manifestations—hemo-
lytic anemia at four years of age and thrombocytopenia at eight years of
age, respectively. P1 received immunosuppressive therapy over a five-
year period and was finally splenectomized. As soon as lymphopenia
and hypogammaglobulinemia were diagnosed, patients were started
on immunoglobulin substitution. Although under treatment, P1 and P2
both died from a septic shock. P3, P4, and P5 currently remain alive, sup-
ported by immunoglobulin substitution and antibiotic prophylaxis (in P3
and P4). In accordance with the Helsinki Declaration, informed consent
for our study was obtained from the families. This study was also ap-
proved by the (INSERM) Institutional Review Board. Primary skin fibro-
blasts were obtained from skin biopsies of all five patients as well as
RS-SCID, Lig4, Ataxia telangiectasia, Nijmegen breakage syndrome pa-
tients in addition to normal controls. SV40-transformed and telomerase-
immortalized cell lines were obtained as described (Nicolas et al., 1998;
Poinsignon et al., 2004).
Antibodies
Rabbit polyclonal anti-phospho-histone H3 and anti-phospho-H2A-X
(Ser139) came from Upstate (Lake Placid, NY). Mouse monoclonal anti-
bodies directed against MRE11 (clone 12D7) and RAD51 (clone 14B4)
originated from Abcam (Cambridge, UK). Alexa-568 and Alexa-488
goat-F(Ab0)2 secondary antibodies were from Molecular probes (Eugen,
OR). FITC-conjugated anti-BrdU antibody and goat F(Ab0)2 anti-rabbit im-
munoglobulin G were purchased from Becton Dickinson (Mountain View,
CA). Mouse monoclonal anti-V5 antibody came from Invitrogen.
IR Sensitivity Assay
IR sensitivity was analyzed by clonogenic assays upon g rays exposure of
primary fibroblasts, as previously described (Nicolas et al., 1998). For IR
sensitivity complementation analysis, primary fibroblasts were trans-
duced using a bicistronic Cernunnos-iresGFP-expressing retrovirus and
subjected to various doses of g rays (0, 1, 3 Gy).
Immunofluorescence Detection of IRIFs
Primary fibroblasts were seeded on cover slips and X-irradiated (Faxitron-
160FW, EDIMEX, Wheeling, IL; 10 Gy; 166 rad/min). Two hours after irra-
diation, cells were washed with PBS and fixed with 4% paraformaldehyde
in PBS for 15 min. After each step, the cover slips were rinsed three times
with PBS. Cells were incubated for 20 min with PBS containing 0.1M gly-
cine and permeabilized in 0.5% Triton X-100 in PBS for 15 min. Cells were
incubated for 30 min with the PBS-BSA solution. Cells were then labeled
with the appropriate primary antibodies, followed by washes with PBS-
BSA solution and incubation with secondary antibodies. Slides were
counterstained with 0.1 mg/ml of DAPI (40, 60-diamidino-2-phenylindole)
and mounted in Fluorsave (Calbiochem). Slides were viewed by epifluor-
escence microscopy (Axioplan ZEISS), and images were taken by
a cooled charge-coupled device (CCD) camera. Grayscale images were
processed using Adobe Photoshop 5.5. (San Jose, CA).gH2AX Detection by Fluorocytometry
Fibroblasts were incubated at 37ºC with medium alone or containing
10 mg/ml of Bleomycin (Aventis) for 1 hr and then washed and incubated
in complete medium. Thirty minutes or 24 hr later, cells were harvested
and fixed in ethanol 70%. Permeabilization was performed with 0.1% tri-
ton X-100 and 4% FBS. Cells were resuspended with anti-gH2AX anti-
body (dilution 1:500) and incubated for 2 hr. Cells were washed and re-
suspended with a 1:1000 dilution of goat anti-mouse IgG (Alexa 488)
for 1 hr. Samples were washed and analyzed by a Becton Dickinson
FACScan flowcytometer.
Cell-Cycle Analysis
G1/S checkpoint analysis was performed as previously described
(Moshous et al., 2003). For G2/M checkpoint analysis, 3  105 immortal-
ized SV40-transformed fibroblasts were harvested 1 hr after 5 Gy X-irra-
diation, washed with PBS, fixed with cold 70% ethanol, and kept at –20ºC
for 16 hr. After washing, the cells were resuspended in PBS 0.25% with
Triton X-100 and incubated on ice for 15 min. Cells were washed in
PBS and incubated with 1 mg of anti-phospho-H3 in PBS-1% BSA for
3 hr. Anti-P-H3 was detected with FITC-conjugated F(Ab0)2 goat anti-rab-
bit IgG antibody. The cells were washed and resuspended in PBS con-
taining 25 mg/ml PI. Fluorescence was measured by using a Becton Dick-
inson FACScan flowcytometer. For RDS assay, primary fibroblasts were
pulse-labeled for 2 hr with 10 ml of [3H]thymidine (1.5 MBq/ml) 45 min fol-
lowing 0 to 40 Gy IR exposure.
In Vivo Plasmid Religation Assay
Five mg of a modified version of EGFP-N2 plasmid (Clontech) were linear-
ized by either SacI and KpnI in order to generate 30-30 ends or by Ecl136II
and SmaI in order to generate blunt endsand introduced into SV40-trans-
formed fibroblasts by electroporation. Recircularized plasmids were re-
covered by hirt lysis 48 hr after transfection, and the junctions were
PCR-amplified using primers CMV 50-CGTGTACGGTGGGAGGTC-30
and GFPr 50-CGGACACGCTGAACTTGTGG-50. PCR products were
cloned in pGemT (Promega) and sequenced.
V(D)J Recombination Assay
V(D)J recombination on extra chromosomal substrates was performed as
previously described using full-length human Rag1 and Rag2 (Nicolas
et al., 1998; Moshous et al., 2001). The pRecCS V(D)J recombination re-
porter substrate has RSS in an orientation which drives V(D)J recombina-
tion by inversion, thus retaining both coding and signal joins, these then
being PCR-amplified using specific combinations of primers. For comple-
mentation analysis in fibroblasts, 2.5 mg of wtCernunnos cloned in
pCDNA3.1D (Invitrogen) was cotransfected. V(D)J recombination assay
on chromosome integrated substrate was performed as previously de-
scribed (Poinsignon et al., 2004).
In Vitro NHEJ Assay
Whole-cell extracts (WCE) preparation and in vitro NHEJ assay were per-
formed using a procedure adapted from Baumann et al. and Diggle et al.
(Baumann and West, 1998; Diggle et al., 2003). Briefly, after washing in
1 PBS, cells were lysed through three freeze/thaw cycles in LB buffer
(25 mM Tris [pH 7.5], 333 mM KCl, 1.3 mM EDTA, 4 mM DTT, protease
and phosphatase inhibitors). Lysates were incubated for 20 min at 4ºC
and cleared by centrifugation. Supernatants were dialyzed against 1 E
buffer (20 mM Tris [pH 8.0], 20% glycerol, 0.1 M K(OAc), 0.5 mM
EDTA, 1 mM DTT). WCE were adjusted to 5 mg/ml and kept frozen
(80ºC) until use. For NHEJ assay, 15 mg of WCE was incubated (10 ml
reaction) with 25 ng of linear DNA (EcoRI digested pEGFPN2) in 1
LigB (250 mM Tris [pH 8.0], 300 mM K(OAc), 2.5 mM Mg(OAc)2, 5 mM
ATP, 5 mM DTT, 0.5 mg/ml BSA, 1 mg/ml IP6) for 2 hr at 37ºC. Reactions
were then treated with 1 ml RNase (1 mg/ml) for 5 min at RT and with 2 ml of
5 deproteination solution (10 mg/ml Proteinase K, 2.5% SDS, 50 mM
EDTA, 100 mM Tris [pH 7.5]) for 30 min at 55ºC. After migration of the
samples in 0.7% agarose, the gels were stained with SYBR-Green
(30 min), and fluorescence was detected via a FluorImager.Cell 124, 287–299, January 27, 2006 ª2006 Elsevier Inc. 297
cDNA Complementation Cloning
SV40-transformed, telomerase-immortalized fibroblasts from P2 were
transduced with a commercially available human thymic cDNA library
cloned into the pFB retroviral vector (ViraPort XR Plasmid Human Thymus
cDNA library, Stratagene) as described (Moshous et al., 2003). Trans-
duced cells were kept in culture for 88 days. During this time period,
they were treated nine times with bleomycin (0.5 mg/ml in RPMI for 1 hr).
cDNA inserts were recovered from genomic DNA by PCR-amplification
using vector-specific primers FBP1 (50-CCTCAAAGTAGACGGCATCGC
AGCTTGGAT-30) and FBP2 (50-CGAACCCCAGAGTCCCGCTCAGAAGA
ACT-30). PCR bands were gel-purified and directly sequenced using FBP1
and subsequent internal primers. The Cernunnos ORF was PCR-amplified
(F1 CACCTCGCCACATGGAAGAACTGGAGCAA, R1 ACTGAAGAGACC
CCTTGCCCTTCTTCC) and cloned with a C terminus V5-epitope/6xHis
tag in pCDNA3.1D (Invitrogen) and a C terminus myc-epitope/6xHis tag
in the retroviral vector pMND-MFG (Robbins et al., 1998). The genomic or-
ganization ofCernunnos gene was determined in silico through Blast anal-
ysis of the cDNA against human genomic sequences.
Cernunnos Gene Sequencing and Expression Analysis
The eight exons ofCernunnoswere PCR-amplified by using genomic DNA
and Taq High Fidelity polymerase (Roche Diagnostics, Mannheim, Ger-
many) in addition to the following oligonucleotide primer pairs: 1F 50-
CCGCCCACGCCAGGCATAGG-30, 1R 50-GGCTTCGTCGCACCAAACA
GG-30; 2F 50-GTTGATACAGACTGGTTTGG-30, 2R 50-TCAACCCGATTC
AACCTTCC-30; 3F 50-TTGCCTTCGTGTTAACCAGG-30, 3R 50-CTAAAG
CTTCCTCTCAAAGC-30; 4F 50-ATGTAAATGGGTTACTTGCC-30, 4R 50-
GTTTCTGGTTAGTATTCAGC-30; 5F 50-CCTCCTCTTTCCTAAGTAGC-
30, 5R 50-AGACAAAGGGCATTCCAACC-30; 6F 50-CCCCTATTGGATCT
AACTGC-30, 6R 50-TCATATTGGACAGCATAAACC-30; 7F 50-TATTTGTA
CCAAACCCTGG-30, 7R 50-GCAATTCCAGGGACCACTGG-30; 8F 50-
CATGAGAGGAAGAAAGTTCC-30, 8R 50-ATTCTCAGAGACTGGCTT
CC-30. RT-PCRs were performed with primers Cernunnos-F 50-TTTCGGT
TCGCGCGAGCGGG-30 and Cernunnos-R 50-CACTATTTTAGAAATATT
GC-30. All PCR products were directly sequenced. PCR-ready cDNAs
from several tissues (Clontech) were amplified with primers Cernu-F 50-
TTGATTCGTCCTCTGATGGG-30 and Cernunnos-R or G3PDH primers.
They were then run onto 1% agarose gels, and bands were stained with
ethidium bromide.
Supplemental Data
Supplemental Data include four figures and can be found with this article
online at http://www.cell.com/cgi/content/full/124/2/287/DC1/.
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